Structure Therapeutics Statistics
Share Statistics
Structure Therapeutics has 19.18M
shares outstanding. The number of shares has increased by 0.42%
in one year.
| Shares Outstanding | 19.18M |
| Shares Change (YoY) | 0.42% |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | 38.37% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 201 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 9.32M, so 16.2% of the outstanding
shares have been sold short.
| Short Interest | 9.32M |
| Short % of Shares Out | 16.2% |
| Short % of Float | 23.38% |
| Short Ratio (days to cover) | 12.66 |
Valuation Ratios
The PE ratio is -43.01 and the forward
PE ratio is -14.97.
Structure Therapeutics's PEG ratio is
-8.6.
| PE Ratio | -43.01 |
| Forward PE | -14.97 |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 6.09 |
| P/FCF Ratio | -44.68 |
| PEG Ratio | -8.6 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Structure Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.74,
with a Debt / Equity ratio of 0.
| Current Ratio | 24.74 |
| Quick Ratio | 24.74 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.03 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-751,693.25 |
| Employee Count | 163 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 310K |
| Effective Tax Rate | -0.25% |
Stock Price Statistics
The stock price has increased by -36.4% in the
last 52 weeks. The beta is -1.79, so Structure Therapeutics's
price volatility has been lower than the market average.
| Beta | -1.79 |
| 52-Week Price Change | -36.4% |
| 50-Day Moving Average | 21.86 |
| 200-Day Moving Average | 30.04 |
| Relative Strength Index (RSI) | 39.75 |
| Average Volume (20 Days) | 952,364 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -158.23M |
| Net Income | -122.53M |
| EBITDA | -158.23M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.63 |
Full Income StatementBalance Sheet
The company has 169.51M in cash and 3.86M in
debt, giving a net cash position of 165.65M.
| Cash & Cash Equivalents | 169.51M |
| Total Debt | 3.86M |
| Net Cash | 165.65M |
| Retained Earnings | -329.1M |
| Total Assets | 866.55M |
| Working Capital | 813.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -116.64M
and capital expenditures -1.29M, giving a free cash flow of -117.93M.
| Operating Cash Flow | -116.64M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -117.93M |
| FCF Per Share | -0.2 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
